Compare Neurocrine Biosciences Inc (NBIX) vs Williams Companies Inc (WMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Williams Companies Inc — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Williams Companies Inc trades at $75.29 (market cap $92.75B). The key difference: Williams Companies Inc is far larger — about 5.9× Neurocrine Biosciences Inc's market cap, and Williams Companies Inc pays a 2.77% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | WMB | |
|---|---|---|
Market Cap | $15.77B | $92.75B |
Sector | Health | Energy |
52-Week High | $185.50 | $79.40 |
52-Week Low | $123.10 | $56.51 |
Enterprise Value | $15.78B | $123.38B |
Dividend Yield | — | 2.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Williams Companies (WMB) trades at $75.83, up 2.27% with strong analyst support (79% buy ratings) and a $88.14 consensus target. The stock shows bullish technical momentum above key support at $74, supported by recent acquisitions and stable dividend payments. Fundamentals reveal robust profitability with 63.26% gross margins and 25.18% net income margin, though valuation multiples remain elevated with P/E at 30.21.
WMB offers exposure to growing natural gas infrastructure demand with recent $5.5 billion Momentum Midstream acquisition expanding Gulf Coast presence. Risks include regulatory challenges as seen with NJ pipeline permit reversal and elevated debt levels at 52% debt-to-asset ratio. The stock presents growth potential through LNG export expansion but faces execution risks on major projects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
